This research study, conducted by the independent economic research institute WifOR, investigates the direct economic impact of selected companies of the pharmaceutical industry in Europe as well as their contribution to the entire European economy from 2010 to 2014. Thus, the study analyses the European Economic Footprint of selected pharmaceutical com- panies. In addition to direct economic effects, the Economic Footprint also accounts for indi- rect and induced economic effects (so-called spillover effects). Direct effects describe a company’s immediate economic impact while indirect effects are a result of inputs or inter- mediate consumption. Induced economic effects originate in the spending of income by em- ployees working in the pharmaceutical industry and for its suppliers. The economic impact analysis is based on the United Nations’ System of National Accounts (SNA). In a first step, a satellite account of the selected pharmaceutical companies is modelled to derive their direct economic effects. In a second step, the indirect and induced economic effects are computed based on the Leontief Inverse. Thus, the economic impact analysis yields direct, indirect and induced gross value added and employment effects in the European economy supported by the selection of European pharmaceutical companies. In addition to these economic impacts, economic key indicators such as R&D intensities are also derived.